Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111 In/ 177 Lu Theranostics

Key Points

• This research aims to develop a new radioligand that specifically targets the cholecystokinin 2 receptor (CCK2R) for cancer therapy.
• Developed Lu-MGS5-DA as a radiotheranostic pair targeting CCK2R-expressing cancers.
• Conducted preclinical evaluations to assess effectiveness and binding affinity of the new radioligand.
• Demonstrated significant tumor targeting in CCK2R-expressing cancer models.
• Showed improved therapeutic outcomes compared to existing treatments.